ANGO

AI Memo

AngioDynamics

As of 2026-09-05/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-05 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

NanoKnife reimbursement and clinical/regulatory follow-through • 2026-12-04

Base target: $19 / p=55% prob

Biggest risk

ANGO remains loss-making on both GAAP and adjusted measures, Med Device growth was modest, and tariff-related headwinds remain. Low analyst coverage and the absence of a reported target count make the bullish re-rating case less reliable.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

The latest company-reported results showed 8.0% pro forma quarterly revenue growth, 16.7% Med Tech growth, positive adjusted EBITDA, and a Medicare coverage pathway for NanoKnife. Continued adoption could narrow the valuation gap to the packet's $20 analyst median target.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-05

Base target

$19

p=55%

Bull target

$22

p=25%

Bear target

$13

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Persistent losses and uneven segment momentum
Sustained Med Tech growth and operating leverage
The latest company-reported results showed 8.0% pro forma quarterly revenue growth, 16.7% Med Tech growth, positive adjusted EBITDA, and a Medicare coverage pathway for NanoKnife.

BearKey bullets

Execution risk in converting NanoKnife coverage and clinical milestones into procedure volume and revenue.
Low analyst coverage and unavailable target-count data reduce confidence in consensus valuation.
Med Device stagnation, tariff pressure, or unfavorable product mix could limit margin expansion.

WatchKey bullets

NanoKnife reimbursement and clinical/regulatory follow-through

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $19 (p=55%)

Target spread vs base: +16% / -34%

Scenario probabilities

Bull Target: $22 (p=25%)Base Target: $19 (p=55%)Bear Target: $13 (p=20%)

Commentary

Recent earnings coverage was constructive on revenue growth and Med Tech execution, while the stored context reported shares up 8.9% since the prior earnings report and flat after-hours reaction immediately after the print. Social, options, short-interest, and employee-sentiment data were not supplied; analyst revision evidence is also unavailable, so confidence remains moderate despite strong primary filing support.

As of 2026-09-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Persistent losses and uneven segment momentum
Sustained Med Tech growth and operating leverage

Scenarios

Bull Target (Scenario probability)

$22 / p=25% prob

Base Target (Scenario probability)

$19 / p=55% prob

Bear Target (Scenario probability)

$13 / p=20% prob

Analysis 2026-09-05 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-04
NanoKnife reimbursement and clinical/regulatory follow-through
Fiscal 2026 results highlighted a Medicare coverage pathway for NanoKnife in qualifying prostate and liver cancer patients, FDA IDE approvals for AlphaReturn and PAVE, and initiation of AMBITION BTK and RECOVER-AV trials. Commercial adoption and trial execution are the main forward variables [#SEC-8K-2026-07-14].
Prob 60.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Persistent losses and uneven segment momentum
2026-10-31
The earnings release showed a fourth-quarter adjusted loss of $0.07 per share and only 1.1% pro forma growth in Med Device revenue. A failure to convert Med Tech growth into durable profitability, or continued tariff and execution pressure, could drive downside [#SEC-8K-2026-07-14].
Prob 45% • Move -12% • Priced-in 40%

Long-term Catalysts

Months to a year

Sustained Med Tech growth and operating leverage
2027-05-31
Fiscal 2026 Med Tech revenue grew 18.4% pro forma, with total revenue growth, positive adjusted EBITDA, and $53.9 million of cash. Continued Auryon, thrombectomy, and NanoKnife execution could support further margin and valuation improvement, although this remains a low-coverage thesis [#SEC-8K-2026-07-14].
Prob 55% • Move 25% • Priced-in 30%

Risks

Execution risk in converting NanoKnife coverage and clinical milestones into procedure volume and revenue.
Low analyst coverage and unavailable target-count data reduce confidence in consensus valuation.
Med Device stagnation, tariff pressure, or unfavorable product mix could limit margin expansion.
Persistent GAAP and adjusted losses despite Med Tech growth.
Recent officer dispositions were reported, but the packet does not establish an operating interpretation; insider activity should not be treated as evidence of results [#SEC-FORM4-2026-07-31].

Peers

Symbol	Summary
BWAY	Same-sector, similar-size reference comparator, but the business exposure is not a close match; useful mainly for small-cap medtech valuation context.
KIDS	Same-sector, similar-size device comparator; useful for small-cap medtech execution context, though product and procedure exposure differ materially.
BSX	Large diversified medtech scale comparator; useful for sector sentiment and valuation context but not a direct size or business-model peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-05

Loading AI feed…

Symbol

Summary

BWAY

Same-sector, similar-size reference comparator, but the business exposure is not a close match; useful mainly for small-cap medtech valuation context.

KIDS

Same-sector, similar-size device comparator; useful for small-cap medtech execution context, though product and procedure exposure differ materially.

BSX

Large diversified medtech scale comparator; useful for sector sentiment and valuation context but not a direct size or business-model peer.